Jeremy Adam Ryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jeremy Adam Ryan has a total of 685 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Letai
Dana-Farber Cancer Institute, Boston, USA
107 shared publications - Jacqueline S. Garcia
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
56 shared publications - Marlise R. Luskin
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
53 shared publications Anthony Letai
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
45 shared publications- David M. Weinstock
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
36 shared publications - Ahmed M. Mamdouh
Department of Pharmacy, National University of Singapore, Singapore
35 shared publications
Latest Publications
- 25 September 2026
- Published by American Society of Hematology in Blood
Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia
In relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), responses to the CD22 antibody-drug conjugate inotuzumab ozogamicin (INO) are frequent but short-lived. Based on preclinical evidence of synergy, we conducted a phase 1 trial of the BCL-2 inhibitor venetoclax (VEN) plus standard-dose INO for adults with R/R CD22+ ALL/LBL. Twenty-three patients enrolled (15 ALL, 8 LBL): three at dose level 1 (DL1; VEN 200 mg/day), six at DL2 (VEN 400 mg/day), and fourteen in an expansion cohort (VEN 400 mg/day). The recommended dose was VEN 400 mg/day for 21 days per cycle. No dose-limiting toxicities or early mortality occurred. Patients received a median of 2 cycles (range 1-5). The most common grade ³3 adverse events were thrombocytopenia (43.5%) and neutropenia (39.1%). Four patients (17.4%) developed sinusoidal obstructive syndrome. Of 22 evaluable patients, 21 (95.5%) achieved complete remission, including 19 after one cycle. Measurable residual disease (MRD) cleared in 16/18 (88.9%) by flow cytometry (<10-4) and 14/19 (73.7%) by next-generation sequencing (<10-6). Fourteen (63.6%) patients proceeded to HSCT. With a median follow-up of 25.3 months (95% CI 19.0-32.4), two-year disease-free (DFS) and overall survival (OS) were 48% (95% CI 24-72%); median DFS was 22.1 months (95% CI 10.4-NA), and median OS was not reached. MRD-positivity was associated with lower baseline BCL-2 dependence. Correlates of progression included acquired MCL-1 dependence, CD22 antigen escape, drug efflux gene ABCB1 expression, and oncogenic mutations. In summary, VEN+INO is safe and effective for R/R B-ALL/LBL, producing frequent and durable MRD-negative remissions. NCT05016947
- 25 September 2026
- Published by American Society of Hematology in Blood
Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia
In relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), responses to the CD22 antibody-drug conjugate inotuzumab ozogamicin (INO) are frequent but short-lived. Based on preclinical evidence of synergy, we conducted a phase 1 trial of the BCL-2 inhibitor venetoclax (VEN) plus standard-dose INO for adults with R/R CD22+ ALL/LBL. Twenty-three patients enrolled (15 ALL, 8 LBL): three at dose level 1 (DL1; VEN 200 mg/day), six at DL2 (VEN 400 mg/day), and fourteen in an expansion cohort (VEN 400 mg/day). The recommended dose was VEN 400 mg/day for 21 days per cycle. No dose-limiting toxicities or early mortality occurred. Patients received a median of 2 cycles (range 1-5). The most common grade ³3 adverse events were thrombocytopenia (43.5%) and neutropenia (39.1%). Four patients (17.4%) developed sinusoidal obstructive syndrome. Of 22 evaluable patients, 21 (95.5%) achieved complete remission, including 19 after one cycle. Measurable residual disease (MRD) cleared in 16/18 (88.9%) by flow cytometry (<10-4) and 14/19 (73.7%) by next-generation sequencing (<10-6). Fourteen (63.6%) patients proceeded to HSCT. With a median follow-up of 25.3 months (95% CI 19.0-32.4), two-year disease-free (DFS) and overall survival (OS) were 48% (95% CI 24-72%); median DFS was 22.1 months (95% CI 10.4-NA), and median OS was not reached. MRD-positivity was associated with lower baseline BCL-2 dependence. Correlates of progression included acquired MCL-1 dependence, CD22 antigen escape, drug efflux gene ABCB1 expression, and oncogenic mutations. In summary, VEN+INO is safe and effective for R/R B-ALL/LBL, producing frequent and durable MRD-negative remissions. NCT05016947
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S7: Reasons for study discontinuation.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S7: Reasons for study discontinuation.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S1: Study representativeness table.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S1: Study representativeness table.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S2: Treatment dose-levels. For cycle 1, venetoclax dosing followed a ramp-up from days 1 to 3 and navitoclax dosing began on day 3 only if platelets remained ≥10 × 109/L (platelet transfusions allowed thereafter).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S2: Treatment dose-levels. For cycle 1, venetoclax dosing followed a ramp-up from days 1 to 3 and navitoclax dosing began on day 3 only if platelets remained ≥10 × 109/L (platelet transfusions allowed thereafter).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S3: Patient-by-patient characteristics.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S3: Patient-by-patient characteristics.